Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anagrelide Retard vs Immediate Release in Essential Thrombocythemia
NCT02076815Phase 3Completed
- Sponsor
- AOP Health
- Start
- Feb 2014
- Primary completion
- Feb 2015
- Modality
- Small Molecules
- Countries
- 5
01
Overview
A Phase 3 trial of anagrelide in essential thrombocythemia (ET), sponsored by AOP Health. Started Feb 2014; status: completed.
02
Drugs
anagrelide
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT02076815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02076815.